SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG (RHHBY) said the U.S. Food and Drug Administration approved Wilserdly, or giredestrant, with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Eligible patients must have an ESR1 mutation detected by an FDA-authorized test and disease that recurred during or after adjuvant endocrine therapy or progressed on at least one endocrine-based regimen in the metastatic setting.
The approval was supported by the Phase 3 evERA Breast Cancer trial. Among patients with ESR1-mutated tumors whose disease progressed after prior CDK4/6 inhibitor therapy, the combination reduced the risk of disease progression or death by 62% versus standard endocrine therapy plus everolimus.
Wilserdly is an oral selective estrogen receptor degrader (SERD) designed to block estrogen signaling and break down the receptor protein that supports cancer growth.
Roche is also seeking approval for Wilserdly as an adjuvant treatment for certain patients with early-stage breast cancer. The New Drug Application (NDA) for Wilserdly is under Priority Review, with an FDA decision expected November 30, 2026.
Additional regulatory filings and development activities are underway outside the United States.
RHHBY closed Monday at $60.95, up 1.08%.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News


